Calling All Investors: Don’t Miss Out on the October 24 Deadline for Origin Materials Inc. Securities Class Action! Rosen, Your Friendly Neighborhood Trial Attorney, Has Got Your Back!

newsmaker04 mins

Welcome to another blog post where we delve into the latest news and updates in the world of finance and securities. Today, we’re talking about a reminder from the Rosen Law Firm regarding Origin Materials, Inc. If you’re an investor in ORGN or ORGNW, you’ll want to pay close attention to the upcoming deadlines. What’s…

Read More

Federal Home Loan Bank of San Francisco’s Teresa Bryce Bazemore Receives 2023 Financial Woman of the Year Award: A Reflection on Her Professional and Leadership Journey

marketinsider03 mins

Federal Home Loan Bank of San Francisco’s Teresa Bryce Bazemore Receives 2023 Financial Woman of the Year Award: A Reflection on Her Professional and Leadership Journey Description: Teresa Bryce Bazemore is Financial Women of San Francisco’s 2023 Financial Woman of the Year. SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Teresa Bryce Bazemore, president and…

Read More

TRxADE Health Inc. Continues to Lead the Pharmaceutical Industry with its Subsidiary, TRxADE Inc., Adding More Members in Q3 2023

marketsgonewild04 mins

TRxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. TAMPA, FL, Oct. 17, 2023 (GLOBE NEWSWIRE) — TRxADE HEALTH, INC. (NASDAQ: MEDS) TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, which recently merged with Superlatus, Inc. (“Superlatus”), today reconfirms its commitment to the…

Read More

Compass Lexecon Expands Economics Team with New Healthcare Expert: Matthew Grennan Joins the Firm

newsit04 mins

FTI Consulting Strengthens Compass Lexecon with New Affiliate, Matthew Grennan Washington, D.C., March 5, 2025 – FTI Consulting, Inc. (NYSE: FCN), a global business solutions provider dedicated to helping organizations manage change, announced the appointment of Matthew Grennan as an affiliate to its economic and financial consulting subsidiary, Compass Lexecon. Background on Matthew Grennan Matthew…

Read More

PepGen Pauses Mid-Stage Trial for Duchenne Muscular Dystrophy Treatment: Stock Drops

newsit05 mins

PepGen Inc. Temporarily Halts Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy On Tuesday, PepGen Inc. (PEPG) made an unexpected announcement regarding the voluntary pause of its Phase 2 CONNECT2-EDO51 study for PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD). Background PGN-EDO51 is an antisense oligonucleotide (ASO) designed to exon-skip and restore the production…

Read More